ABEO vs. QURE, ACRS, EQ, LUMO, ACRX, LBPH, PAHC, GHRS, NUVB, and ABUS
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include uniQure (QURE), Aclaris Therapeutics (ACRS), Equillium (EQ), Lumos Pharma (LUMO), AcelRx Pharmaceuticals (ACRX), Longboard Pharmaceuticals (LBPH), Phibro Animal Health (PAHC), GH Research (GHRS), Nuvation Bio (NUVB), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical preparations" industry.
uniQure (NASDAQ:QURE) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
uniQure presently has a consensus target price of $24.75, indicating a potential upside of 360.04%. Abeona Therapeutics has a consensus target price of $21.00, indicating a potential upside of 370.85%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than uniQure.
In the previous week, Abeona Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Abeona Therapeutics and 0 mentions for uniQure. uniQure's average media sentiment score of 0.35 beat Abeona Therapeutics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
uniQure has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
Abeona Therapeutics has lower revenue, but higher earnings than uniQure. Abeona Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -1,562.22%. Abeona Therapeutics' return on equity of -121.60% beat uniQure's return on equity.
78.8% of uniQure shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 5.3% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
uniQure received 122 more outperform votes than Abeona Therapeutics when rated by MarketBeat users. Likewise, 70.70% of users gave uniQure an outperform vote while only 70.36% of users gave Abeona Therapeutics an outperform vote.
Summary
Abeona Therapeutics beats uniQure on 11 of the 18 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
